TMCnet News
Vantage Issues Synopsis of the FDA's Guidance on Grandfathering for the Drug Supply Chain Security ActHILLSBOROUGH, N.J., Dec. 5, 2017 /PRNewswire/ -- Vantage Consulting Group, a trusted manufacturing automation expert, today announced it has published an interpretation and summary of the recent guidance with regards to 'grandfathering' under the Food and Drug Administration's (FDA) Drug Supply Chain Security Act (DSCSA). The DSCSA outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States, enhancing the FDA's ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. "The DSCSA will make pharmaceuticals safer for consumers, but complying with the act has been a very intense and expensive undertaking for the industry," said John Jordon, vice president, Business Strategies, Vantage Consulting Group. "With the upcoming packaging-ased deadlines, we hope the synopsis unveiled in this paper will help companies understand what needs to be done, when and how it is documented." The paper, which can be downloaded at https://www.vantage-cg.com/professional-development-series/, outlines trading partner requirements under grandfathering for manufacturers, distributors, dispensers and re-packagers. It also features guidance on product implications and saleable returns. About Vantage Consulting Group View original content:http://www.prnewswire.com/news-releases/vantage-issues-synopsis-of-the-fdas-guidance-on-grandfathering-for-the-drug-supply-chain-security-act-300566680.html SOURCE Vantage Consulting Group |